Boulder, CO-based miRagen has racked up its first big collaboration, inking a development pact with France’s Servier for two of its top preclinical programs as well as a third, as yet unidentified, program. In exchange for commercialization rights outside the U.S. and Japan, miRagen gets $45 million in an upfront payment, research support and near-term milestones, up to $352 million in total milestones and double-digit royalties on approved products.

Press Release